Overview

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

Status:
Completed

Trial end date:
2013-11-01

Target enrollment:
0

Participant gender:
All

Summary

Evaluation of efficacy and safety of tofacitinib (CP-690,550) for the treatment of early rheumatoid arthritis in adult patients with moderate to severe disease who are methotrexate naïve. The efficacy will be evaluated by exploring the effects on joint structure assessed by magnetic resonance imaging, x-rays and by standard clinical assessment.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Treatments:

Methotrexate
Tofacitinib

Criteria

Inclusion Criteria:

- Adult patients with moderate to severe early rheumatoid arthritis (< 2 years) who are
methotrexate and biologic disease modifying antirheumatic drug naive.

Exclusion Criteria:

- Pregnant or lactating patients;

- Patients with renal or hepatic impairment or other severe or progressing disease;

- Patients with contraindication to magnetic resonance imaging with gadolinium contrast.